Core Viewpoint - Qianjin Pharmaceutical (600479) confirmed that during the transition period of its acquisition plan, any profits or increases in net assets from the target company will be enjoyed by the listed company [1] Group 1 - The company responded to investor inquiries on an interactive platform regarding its acquisition plan [1] - The increase in investment income for the company in the third quarter was attributed to the investment returns from its stake in the Guohai Guochuang Pharmaceutical Fund [1]

证券日报网讯 12月10日，千金药业在互动平台回答投资者提问时表示，公司2025年三季度披露财务报 表未将收购部分股权的利润纳入归母净利润。两个标的收购股权的财务利润分别在2025年10月、2025年 11月开始并表。 （编辑 王雪儿） ...

每经AI快讯，有投资者在投资者互动平台提问：公司有无流感相关仿制药的立项？ 千金药业（600479.SH）12月10日在投资者互动平台表示，公司有治疗流感相关仿制药立项。 （记者 张明双） ...

关于发行股份及支付现金购买资产暨关联交易 证券代码：600479 证券简称：千金药业 公告编号：2025-060 株洲千金药业股份有限公司 根据上述专项审计报告，在本次交易的过渡期间内，千金湘江药 业实现净利润 135,203,152.10 元，千金协力药业实现净利润 35,252,082.95 元，标的资产均未出现经营亏损，交易对方无需承担 补偿责任，标的资产在过渡期内产生的收益由千金药业享有。 之标的资产过渡期损益情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 株洲千金药业股份有限公司（以下简称"千金药业"或"公司"） 以发行股份及支付现金方式购买湖南千金湘江药业股份有限公司（以 下简称"千金湘江药业"）28.92%的股权及湖南千金协力药业有限公 司（以下简称"千金协力药业"）68.00%的股权（以下简称"本次交 易"）。本次交易的标的资产已全部完成交割过户，公司为支付标的资 产对价新发行的股份已完成上市，现将本次交易标的资产过渡期间损 益相关情况公告如下： 一、关于过渡期损益安排 根据公司与交易各方签订的《附 ...

目 录 | 一、专项审计报告…………………………………………………… | 第 1—3 | 页 | | --- | --- | --- | | 二、资产交割过渡期利润表………………………………………………第 | | 4 页 | | 三、财务报表附注…………………………………………………… | 第 5—27 | 页 | | 四、附件……………………………………………………………第 | 28—31 | 页 | | （一）本所营业执照复印件 …………………………………… | 第 28 | 页 | | （二）本所执业证书复印件 …………………………………… | 第 29 | 页 | | （三）本所签字注册会计师执业证书复印件 ………………第 | 30-31 | 页 | 关于湖南千金湘江药业股份有限公司 过渡期损益情况的专项审计报告 天健审〔2025〕2-499 号 湖南千金湘江药业股份有限公司全体股东： 一、审计意见 我们审计了湖南千金湘江药业股份有限公司（以下简称湘药公司）资产交割 过渡期（2024 年 10 月 1 日至 2025 年 9 月 30 日）的利润表以及相关附注（以下 合称财务报表）。 我们认为，后附的 ...

目 录 | 一、专项审计报告………………………………………………………第 | 1—3 | 页 | | --- | --- | --- | | 二、资产交割过渡期利润表………………………………………………第 | 4 | 页 | | 三、财务报表附注……………………………………………………第 | 5—25 | 页 | | 四、附件………………………………………………………………第 | 26—29 | 页 | | （一）本所营业执照复印件 ………………………………………第 | 26 | 页 | | （二）本所执业证书复印件 ………………………………………第 | 27 | 页 | | （三）本所签字注册会计师执业证书复印件…………………第 | 28—29 | 页 | 专项审计报告 天健审〔2025〕2-520 号 湖南千金协力药业有限公司全体股东： 一、审计意见 我们审计了湖南千金协力药业有限公司（以下简称千金协力药业公司）资产 交割过渡期（2024 年 10 月 1 日至 2025 年 10 月 31 日）的利润表以及相关附注 （以下合称财务报表）。 我们认为，后附的财务报表在所有重大方面按照财务报表附注三所述的编 ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

Core Insights - Qianjin Pharmaceutical's stock price increased by 2.01% on November 25, reaching 10.66 CNY per share, with a market capitalization of 5.247 billion CNY [1] - The company reported a revenue of 2.718 billion CNY for the first nine months of 2025, showing a year-on-year growth of 0.14%, and a net profit of 187 million CNY, up 11.47% year-on-year [2] - The company has distributed a total of 2.375 billion CNY in dividends since its A-share listing, with 449 million CNY distributed in the last three years [3] Company Overview - Qianjin Pharmaceutical, established on August 13, 1993, and listed on March 12, 2004, is located in Zhuzhou, Hunan Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and women's hygiene products, with revenue contributions of 39.95% from drug wholesale and retail, 28.33% from traditional Chinese medicine production, and 28.28% from Western medicine production [1] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.85% to 36,800, while the average circulating shares per person increased by 10.92% to 11,360 shares [2] - Major new institutional shareholders include Invesco Great Wall CSI Dividend Low Volatility 100 ETF and Tianhong CSI Dividend Low Volatility 100 ETF, among others [3]

Group 1 - The company held a Q3 2025 performance briefing on November 20, 2025, to discuss operational results and financial status with investors [1] - The meeting featured participation from the chairman, independent director, board secretary, and financial officer, who addressed investor inquiries [1] Group 2 - The company is expanding its production capacity through new workshops and upgrading existing production lines to meet the demand for new products [2] - The company reported a 32% year-on-year revenue growth in its sanitary products business for Q3 2025, while also focusing on digital transformation and new retail strategies [2] - The company maintains a leading position in the gynecological traditional Chinese medicine market, with a market share of 25.8% for its main product in 2024 [2] Group 3 - The company’s investment in Hunan Newhe Biopharmaceutical Co., Ltd. aims to enhance resource integration and strategic layout within the pharmaceutical industry [4] - The company is currently in the process of integrating three pharmaceutical companies to improve overall synergy [4] - The company’s cash management yields approximately 2% annually [8] Group 4 - The company plans to maintain stable dividends, having consistently provided a high proportion of cash dividends since its listing [6] - The company’s acquisition of Qianjin Xiangjiang and Qianjin Xieli is expected to enhance its performance, with consolidation of financial results starting in October and November 2025 [5] Group 5 - The company is undergoing a digital transformation in its pharmacy operations, shifting from a product-centric to a customer-centric model [9] - The collaboration with Alibaba focuses on building a C-end operation platform and a smart women's health platform [10]

证券代码：600479 证券简称：千金药业 公告编号：2025-059 问题 2：1、注意到本年三季度虽然利润比去年有增长，但相比 株洲千金药业股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"）于 2025 年 11 月 20 日在价值在线（www.ir-online.cn）召开了公司 2025 年第三季 度业绩说明会。本次业绩说明会以网络互动方式召开，公司针对报告 期内经营成果、财务状况与投资者进行互动交流和沟通，在信息披露 允许的范围内就投资者普遍关注的问题进行回答。现将相关情况公告 如下： 一、 业绩说明会召开情况 本次业绩说明会于 2025 年 11 月 20 日（星期四） 15:00-16:00 以网络互动的形式在价值在线（www.ir-online.cn）召开，公司董事 长蹇顺，独立董事马理，董事会秘书朱溧，副总经理兼财务负责人彭 意花参加了本次说明会并就投资者关注的问题进行了回答。 二、本次说明会投资 ...